LAURUSLABS1,942.50

Laurus Labs Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABGLANDMANKINDBIOCONALKEMLUPINFORTISGLENMARKMcap ₹1.05L Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt2,507.12,693.12,397.52,397.5
Net Debt2,368.12,593.52,284.82,284.8
Total Debt/Equity0.610.590.440.44
Net Debt/Equity0.580.560.420.42
Total Debt/EBITDA3.222.551.351.35
Net Debt/EBITDA3.052.461.290.95
Interest Coverage (EBIT/Interest)2.152.897.607.60
Total Debt/Total Capital %37.8636.9130.6230.62
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.